BioSpace News Archive

Revive Therapeutics Ltd. announced today that the U.S. Food & Drug Administration (“FDA”) has responded that a Type C meeting would be recommended, which the Company will request, to discuss the overall development plan and the latest revised endpoints for the Company’s Phase 3 clinical trial (the “Study”) (NCT04504734) to evaluate the safety and efficacy of Bucillamine, an oral drug with anti-inflammatory and antiviral properties, in patients with mild to moderate COVID-19.

LeMaitre Vascular, Inc. announced that it is participating in two upcoming investor conferences.

PHISKIN, a Chinese aesthetic medicine clinics brand, has announced a new enhancement to its one-stop high-end medical service system as part of the expansion of its healthcare business

Novartis will present data on the latest advancements in breast cancer and hematology at the 2022 San Antonio Breast Cancer Symposium (SABCS), December 6-10, and the American Society of Hematology (ASH) Annual Meeting, December 10-13.

JDRF, the leading global type 1 diabetes (T1D) research and advocacy organization, applauds the decision from the U.S Food and Drug Administration (FDA) to approve Provention Bio’s teplizumab.

Athenex, Inc. announced the results of its special meeting of stockholders, held as a virtual meeting on November 22, 2022.

Science 37 Holdings, Inc., the industry-leading Metasite™, and BEKHealth, a leading clinical research platform, announced a partnership that will enable Science 37 to access the EMR data, exclusively, across its network of more than 35 thousand community providers, covering more than 35 million patient lives–expanding participant access, accelerating enrollment, and potentially reducing time to market for important investigational treatments and therapies.

Empatica, a digital health and AI company developing medical-grade wearables and algorithms for health monitoring and diagnostics, today announced the clearance of its Empatica Health Monitoring Platform by the U.S. Food and Drug Administration (FDA).

uLab Systems™, creator of the uSmile™ clear aligner system and uDesign® treatment planning software, announces the establishment of a separate business line to manufacture private-label aligner products.

Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that the EMERALD-2 phase 2b study of MORF-057 in ulcerative colitis (UC) has commenced with the first patient receiving MORF-057.